In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria

Kato, Naoya; Kato, Haru; Tanaka, Yasunori; Bando, Kaori; Watanabe, Kunitomo; Ueno, Kazue

doi:10.1128/aac.37.5.957

Cited by 15 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the latter regard, FK-037 has an activity in common with that of cefepime (3,9), which has been shown to be usually active against isolates of species that are resistant to cefoperazone, cefotaxime, and ceftazidime (1,8,10). While FK-037 was highly active against gram-positive bacteria, its activity against oxacillin-resistant staphylococci was variable, undoubtedly reflecting variabilities in the degree of heterogeneous expression of resistance to oxacillin among the isolates tested.…”

mentioning

confidence: 99%

“…Fu et al (2), Neu et al (14), and Nishino et al (15) have also demonstrated the activity of this compound against isolates of streptococci, including beta-hemolytic groups and Streptococcus pneumoniae, and Haemophilus influenzae. FK-037 has also been shown to be active against a variety of anaerobic bacteria other than the Bacteroides fragilis group (9). Neu et al (14) found that the MICs of FK-037 for 90% of the strains tested (MIC%0s) in the family Enterobacteriaceae were similar to those of cefepime and lower than those of ceftazidime and imipenem but that resistant mutants of Enterobacter cloacae, Citrobacter freundii, and S. aureus could be selected by daily transfer in the presence of FK-037.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

Washington

Jones

Gerlach

et al. 1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

In a multicenter study, the MICs of FK-037 for 90%o of the strains tested (MIC90s) were <1 ,ug/ml for members of the family Enterobacteriaceae other than Citrobacter freundii, Enterobacter spp., and Serratia marcescens. Activity against Pseudomonas aeruginosa was variable, with a MIC50 and a MIC,0 of 4 and 32 ,ug/ml, respectively. Relative to cefepime, however, FK-037 was less active against ceftazidime-resistant isolates of Enterobacter cloacae. The MIC,0 of FK-037 for methicillin-resistant staphylococci was >16 ,ug/ml.FK-037 is a novel injectable oxime-type cephalosporin antibiotic with a 1-hydroxyethyl-5-aminopyrazole moiety at the three position (15). Data presented in abstracts in 1991 and 1992 suggested that FK-037 was more active than currently available extended-spectrum cephalosporins against staphylococci, including methicillin-resistant strains (5,12,15); however, at four times its MIC, FK-037 reduced the number of CFU of methicillin-resistant Staphylococcus aureus by only 1 order of magnitude while vancomycin reduced the number of CFU by over 3 orders of magnitude in killing curve studies (1). In studies by Neu et al. (14), 16 ,ug of FK-037 per ml inhibited 50% of the S. aureus isolates tested with oxacillin MICs of >16 ,ug/ml. FK-037 has also been reported to have a broad spectrum of activity against gram-negative bacilli, including members of the family Enterobacteriaceae and Pseudomonas aeruginosa, and to be active against many ceftazidime-resistant isolates of Citrobacter spp., Enterobacter spp., and P. aeruginosa (2, 4-7, 11, 13, 16

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

Washington

Jones

Gerlach

et al. 1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Among anaerobic bacteria, B. fragilis has generally been found to be resistant to the zwitterionic 7-methoxyimino cephalosporins, but the combination of cefpirome with tazobactam enhanced the antibactericidal activity of the former (Watanabe et al, 1988;Fujimoto et al, 1990;Jones et al, 1990;Kato et al, 1993;Neu et al, 1993). MIQoS of cefpirome and FK037 < 1 mg/L have been determined for Clostridium perfringens, Peptostreptococcus anaerobius and Peptostreptococcus asacharolyticus, Porphyromonas gingivalis, Mobiluncus spp.…”

Section: Strict Anaerobesmentioning

confidence: 99%

“…MIQoS of cefpirome and FK037 < 1 mg/L have been determined for Clostridium perfringens, Peptostreptococcus anaerobius and Peptostreptococcus asacharolyticus, Porphyromonas gingivalis, Mobiluncus spp. and Gardnerella vaginalis (King, Boothman & Phillips, 1990;Limbert et al, 1992;Kato et al, 1993). Tauber el al.…”

Section: Strict Anaerobesmentioning

confidence: 99%

Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins

Péchère¹,

Wilson²,

Neu³

1995

J Antimicrob Chemother

View full text Add to dashboard Cite

“…and Prevotella bivia, whereas its activity against Bacteroides fragilis and Clostridium spp. is weak [14,15].…”

Section: Introductionmentioning

confidence: 99%

Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections

Rafailidis

Polyzos

Sgouros

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

To cite this version:Petros I. Rafailidis, Konstantinos A. Polyzos, Konstantinos Sgouros, Matthew E. Falagas.Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.International Journal of Antimicrobial Agents, Elsevier, 2011, 37 (4) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In summary, prulifloxacin appears to be a promising agent for the treatment of bacterial prostatitis and traveller's diarrhoea.

show abstract

In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria

Abstract: The activity of FK037, a

Cited by 15 publications

References 18 publications

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins

Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections

Contact Info

Product

Resources

About